Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24600919 | 0.93 | ADORA3 (0.39) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24601134 | 0.92 | ADORA3 (0.39) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24601100 | 0.92 | NT5E (0.40) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24601240 | 0.92 | NT5E (0.42) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24600934 | 0.92 | KCNA5 (0.44) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24600901 | 0.91 | ADORA2A (0.44) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24600693 | 0.91 | NT5E (0.42) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24600687 | 0.90 | ADORA3 (0.45) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24600898 | 0.88 | KCNH2 (0.40) | NT5EADORA3KCNH2KCNA5ADORA2A | |
| SCHEMBL24601093 | 0.87 | ADORA3 (0.39) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022143740-A1 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江春禾医药科技有限公司 | 2022-07-07 | — | — | WO | disclosed |